Sterile Injectable Drugs Market Size & Share, by Type (Small Molecule, Large Molecule); Drug Class (Insulin, Hormones, Vaccines, Peptide Antibiotic, Cytokines); Application (Pain, Infections, Autoimmune Disease, Diabetes, Cardiovascular Diseases); Distribution Channel (Hospitals, Pharmacy, Ambulatory Surgical Centers)- Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

Request Free Sample Copy

Report ID: 3050
Published Date: Dec 24, 2024
Report Format: PDF, PPT

Buy Now

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Sterile Injectable Drugs Market size was valued at USD 636.21 billion in 2024 and is set to exceed USD 1.21 trillion by 2037, registering over 5.1% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of sterile injectable drugs is evaluated at USD 663.79 billion.

The growth of the market can be attributed to the rising prevalence of chronic diseases around the globe, along with rising health awareness among people and authorities. Government initiatives to curb spread of diseases in the form of investment in healthcare sector, and vaccination drives, among others, is estimated to boost the market growth. Moreover, the COVID-19 pandemic has emphasized the need for more efficient healthcare system, R&D activities for novel treatment methods, and quicker development and approval of drugs, on a global level, which is estimated to boost the market growth significantly in the upcoming years.

Get more information on this report: Request Free Sample PDF

Sterile Injectable Drugs Sector: Growth Drivers and Challenges

Growth Drivers

Rising Prevalence of Diseases
Increasing Need for Vaccines amidst COVID-19 Pandemic

Challenges

Long Time Taken for the Approval of Drugs

Sterile Injectable Drugs Market: Key Insights

Base Year	2024
Forecast Year	2025-2037
CAGR	5.1%
Base Year Market Size (2024)	USD 636.21 billion
Forecast Year Market Size (2037)	USD 1.21 trillion
Regional Scope	North America (U.S., and Canada) Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific) Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Latin America (Mexico, Argentina, Brazil, Rest of Latin America) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Get more information on this report: Request Free Sample PDF

Sterile Injectable Drugs Segmentation

The market is segmented by drug class into insulin, hormones, vaccines, peptide antibiotic, cytokines, and others, out of which, the vaccines segment is anticipated to hold the largest share in the market during the forecast period on account of escalating demand for vaccines for various infectious diseases, with respect to the spread of coronavirus, and other viral and bacterial diseases, including smallpox, measles, rubella, polio, and others. The insulin segment is also anticipated to witness major market share over the forecast period, owing to the rising cases of type 1 and type 2 diabetes.

On the basis of distribution channel, the market is segmented into hospitals, pharmacy, ambulatory surgical centers, and others. Out of these, the hospitals segment is anticipated to witness highest CAGR over the forecast period on the back of higher patient pool, ease of availability, and greater credibility of hospitals over general pharmacies.

Our in-depth analysis of the global market includes the following segments:

By Type	Small Molecule Large Molecule
By Drug Class	Insulin Hormones Vaccines Peptide Antibiotics Cytokines Others
By Application	Pain Infections Autoimmune Diseases Diabetes Cardiovascular Diseases Other
By Distribution Channel	Hospitals Pharmacy Ambulatory Surgical Centers Others

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Regionally, the sterile injectable drugs market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. The market in North America industry is likely to dominate majority revenue share by 2037, led by high investment in healthcare sector, along with increasing medical R&D activities in the region. The market in the Asia Pacific is estimated to witness a noteworthy growth during the forecast period, owing to the improving healthcare sector backed by rising disposable income and economic development in the region.

Get more information on this report: Request Free Sample PDF

Companies Dominating the Sterile Injectable Drugs Landscape

Sanofi-aventis Groupe
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis

Pfizer Inc.
GlaxoSmithKline plc
Bausch Health Companies Inc.
Boehringer Ingelheim International GmbH
AbbVie Inc.
Amgen Inc.
Novartis AG
Progenity, Inc.
Johnson & Johnson Services, Inc.

In the News

· July 07, 2020: GlaxoSmithKline plc (GSK) and Medicago announced their collaboration to develop vaccine for COVID-19

Author Credits: Radhika Pawar

Report ID: 3050
Published Date: Dec 24, 2024
Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of sterile injectable drugs is evaluated at USD 663.79 billion.

Sterile Injectable Drugs Market size was valued at USD 636.21 billion in 2024 and is set to exceed USD 1.21 trillion by 2037, registering over 5.1% CAGR during the forecast period i.e., between 2025-2037.

North America industry is likely to dominate majority revenue share by 2037, led by high investment in healthcare sector, along with increasing medical R&D activities in the region.

The major players in the market are GlaxoSmithKline plc, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, AbbVie Inc., Amgen Inc., Novartis AG, Progenity, Inc., Johnson & Johnson Services, Inc. and others.